Concepedia
Statistics
Publications
13
Citations
1.3K
H-Index
Active since
1997
Affiliations
Bayer (Germany)(Current)
Max Planck Institute for Terrestrial Microbiology
Bayer (United States)
Adrian Tersteegen is an author at Bayer (Germany) specializing in pharmacology, life sciences, and molecular pharmacology.
Publications per year
1997–2023
Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels
Johannes‐Peter Stasch, Péter Schmidt, Pavel I. Nedvetsky et al. · Journal of Clinical Investigation · 2006 · 449 citations · Full text
Life Sciences, Biochemistry, Pharmacology +16
The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents
F. Josef van der Staay, Kris Rutten, Lars Bärfacker et al. · Neuropharmacology · 2008 · 175 citations · Full text
Medicine, Neuroscience, Pharmacology +7
Characterization of the First Potent and Selective PDE9 Inhibitor Using a cGMP Reporter Cell Line
Frank Wunder, Adrian Tersteegen, Annegret Rebmann et al. · Molecular Pharmacology · 2005 · 146 citations
Medicine, Medicinal Chemistry, Pharmacology +13
<i>Methanobacterium thermoautotrophicum</i> encodes two multisubunit membrane‐bound [NiFe] hydrogenases
Adrian Tersteegen, Reiner Hedderich · European Journal of Biochemistry · 1999 · 111 citations · Full text
Life Sciences, Microbiology, Molecular Biology +8
Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase
Colin W. Garvie, Xiaoyun Wu, Malvina Papanastasiou et al. · Nature Communications · 2021 · 90 citations · Full text
Life Sciences, Biochemistry, Molecular Biology +16
1–5 of 13